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Heterogenous Renal Injury Biomarker 
Production Reveals Human Sepsis-
Associated Acute Kidney Injury Subtypes
Daniela Jou-Valencia, BSc1,2; Jacqueline Koeze, MD1; Eliane R. Popa, PhD2; Adnan Aslan , MD1;  
Peter J. Zwiers, BSc2; Grietje Molema, PhD2; Jan G. Zijlstra, MD, PhD1,2; Matijs van Meurs, MD, PhD1,2;  
Jill Moser, PhD1,2
Objectives: To identify mechanisms associated with sepsis-acute kid-
ney injury based on the expression levels of renal injury biomarkers, 
neutrophil gelatinase–associated lipocalin, and kidney injury mole-
cule-1 in renal biopsies which may allow the identification of sepsis-
acute kidney injury patient subtypes.
Design: Prospective, clinical laboratory study using “warm” human 
postmortem sepsis-acute kidney injury kidney biopsies.
Setting: Research laboratory at university teaching hospital.
Subjects: Adult patients who died of sepsis in the ICU and control 
patients undergoing tumor nephrectomy.
Measurements and Main Results: Reverse transcription quantitative 
polymerase chain reaction and immunohistochemical staining were 
used to quantify messenger RNA and protein expression levels of 
neutrophil gelatinase–associated lipocalin and kidney injury mole-
cule-1 in the kidney of sepsis-acute kidney injury patients and control 
subjects. Morphometric analysis was used to quantify renal and glo-
merular neutrophil gelatinase–associated lipocalin and kidney injury 
molecule-1 protein levels. Neutrophil gelatinase–associated lipocalin 
and kidney injury molecule-1 messenger RNA and protein levels were 
increased in kidneys of sepsis-acute kidney injury patients compared 
with control kidney tissue. Neutrophil gelatinase–associated lipocalin 
was localized in the distal tubules, collecting ducts, the adventitia 
of the renal arterioles, and in the glomerular tufts of renal biopsies 
from sepsis-acute kidney injury patients. In contrast, kidney injury mol-
ecule-1 was localized at the brush border of the proximal tubules. 
There was no correlation between neutrophil gelatinase–associated 
lipocalin and kidney injury molecule-1 levels. Furthermore, renal neu-
trophil gelatinase–associated lipocalin and kidney injury molecule-1 
levels were not associated with the extent of renal injury, the severity 
of critical illness, or serum creatinine levels at either ICU admission 
or day of expiration. By laser microdissecting glomeruli, followed by 
reverse transcription quantitative polymerase chain reaction, we iden-
tified heterogenous glomerular neutrophil gelatinase–associated lipo-
calin production in the kidney of sepsis-acute kidney injury patients.
Conclusion: We found differences in the expression of neutrophil gela-
tinase–associated lipocalin and kidney injury molecule-1 in patients 
with the same syndrome “sepsis-acute kidney injury” meaning there 
is no single pathway leading to sepsis-acute kidney injury. This under-
scores the beliefs that there are many/different pathophysiological 
pathways that can cause sepsis-acute kidney injury. Hence, patients 
with criteria that meet the definitions of both acute kidney injury and 
sepsis can be divided into subtypes based on pathophysiological 
features.
Key Words: acute kidney injury; kidney injury molecule-1; neutrophil 
gelatinase–associated lipocalin; sepsis; subtypes
Acute kidney injury (AKI) in critically ill patients is a com-mon heterogeneous syndrome, which, due to the lack of pharmacological therapies, is associated with poor short and 
long-term outcome (1, 2). Because we do not yet fully understand 
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the pathophysiological mechanisms associated with AKI, we still rely 
on a definition to make a clinical diagnosis. The use of (Risk, Injury, 
Failure, Loss of kidney function, End-stage renal disease [RIFLE], 
Acute Kidney Injury Network, or Kidney Disease Improving Global 
Outcomes [KDIGO]) definitions alone is inadequate (3) because they 
do not address underlying, potentially heterogenous pathophysiolog-
ical mechanisms, which, once better understood, may allow individ-
ualized therapy. Furthermore, these definitions are based on serum 
creatinine levels, which increase only 24–48 hours after declining 
renal function (4). Sepsis-associated AKI (sepsis-AKI) is even more 
enigmatic because it is clinically diagnosed based on a set of symp-
toms (5). Sepsis-AKI can be caused by different pathogens in patients 
of different ages and with diverse comorbidities and, therefore, can 
assume different pathophysiologies, severities of illness, response to 
treatment, and outcome. Recently, two AKI subphenotypes based 
on plasma biomarkers and clinical variables were found to respond 
differently to vasopressin therapy (6). These subphenotypes are strik-
ingly similar to the acute respiratory distress syndrome (ARDS) sub-
phenotypes also recently identified (7–9). Because plasma biomarkers 
are an accumulation of proteins from different cells and organs, the 
identified AKI and ARDS phenotypes may more accurately represent 
subphenotypes of critical illness with multiple organ failure, rather 
than AKI or ARDS, specifically. If we are ever to find a therapy that 
will benefit AKI patients by reversing and/or limiting organ injury, it 
must be directed toward the pathophysiology of renal injury because 
this offers the best chance of success.
The quest for AKI biomarkers has revealed a plethora of molecules 
increased in the plasma and/or urine of patients (10), yet none are 
currently used in clinical practice. neutrophil gelatinase–associated 
lipocalin (NGAL) and kidney injury molecule (KIM)-1 are promising 
markers of both sepsis severity and renal injury (11), and in response 
to an acute insult are involved in renal protection and recovery (12). 
Plasma NGAL and KIM-1 increase a few hours after the initial insult 
and can persist for days to weeks (13). However, NGAL and KIM-1 
are not increased to a similar extent in all AKI patients (13). Similarly, 
unique renal transcriptional patterns were found in mice with a simi-
lar AKI stage but due to differing etiologies (14). Experimental animal 
models have shown that renal NGAL is increased after both lipopoly-
saccharide (LPS) and ischemia-reperfusion injury (IRI), whereas 
KIM-1 was increased as a result of IRI only (15). Furthermore, NGAL 
and KIM-1 staining in renal allograft biopsies showed a different dis-
tribution and localization (16), with similar findings observed in chil-
dren with prerenal and intrinsic AKI (17). Thus, the production of 
NGAL and KIM-1 appears to be etiology dependent.
We hypothesized that heterogenous renal responses to sepsis 
would result in variable expression of injury-related biomarkers 
which may be associated with specific pathophysiological mecha-
nisms. The aim of this study was, therefore, to identify possible 
mechanisms associated with sepsis-AKI based on the expression 
levels of the renal injury biomarkers, NGAL, and KIM-1, which 
may allow identification of sepsis-AKI patient subtypes.
MATERIALS AND METHODS
Patients
Postmortem kidney biopsies were collected from patients with 
sepsis and AKI, as described elsewhere (18). Patients 18 years 
old and older who died of sepsis in the ICU were included in the 
study. Patients with pre-existing chronic kidney disease, active 
autoimmune disorders with renal involvement, and treatment 
with immune-suppressive medication were excluded from this 
study. All patients were classified as having septic shock accord-
ing to the International Sepsis Definitions (19). In addition, AKI 
in all patients was classified according to the RIFLE criteria, using 
serum creatinine and urine output (20). The severity of critical 
illness was defined upon admission to the ICU using the Acute 
Physiology and Chronic Health Evaluation (APACHE) IV and the 
Simplified Acute Physiology Score (SAPS) II scoring system (21, 
22). In patients undergoing complete nephrectomy as a result of 
kidney cancer, a healthy part of tissue was isolated from the kidney 
cortex as far away as possible from the tumor. A dedicated renal 
pathologist at our hospital assessed these biopsies and considered 
them to be normal. Thus, we forthwith refer to these biopsies as 
healthy controls. Patients with previous renal function loss were 
excluded. All biopsies were taken within an average of 33 minutes 
after death at the bedside in our ICU, or in the operating theater, 
immediately after removal of the kidney in nephrectomy patients, 
and are therefore considered “warm.” These measures were taken 
to avoid necrosis. Immediate postmortem biopsies are performed 
by definition in deceased patients. Therefore, legal regulations for 
studies in alive patients do not apply. We considered our imme-
diate postmortem biopsies as a limited autopsy. Full autopsy was 
also offered to the relatives of the patients. The limited autopsy 
was performed under the responsibility of the clinicians and 
pathologist with the purpose to explore the cause of renal failure. 
Permission and written informed consent for this limited autopsy 
were asked for and obtained in the final family meeting before or 
just after death. The limited autopsy procedure was explained in 
detail, and we mentioned that we would try to make the cause 
of death clearer and that we furthermore had a research purpose. 
An autopsy report of the routine histological findings was added 
to the patient chart and was discussed during a meeting with the 
family 6 weeks after discharge (death). Control biopsies were 
obtained from patients who underwent total nephrectomy as a 
result of kidney cancer. All renal cancer patients gave preoperative 
consent. The Medical Ethics Review Committee (METC) of the 
University Medical Center Groningen reviewed and waived this 
study (METc 2011/372). Patient characteristics and clinical and 
laboratory details can be found in Tables 1 and 2.
Gene Expression Analysis by Reverse Transcription 
Quantitative Polymerase Chain Reaction
RNA was isolated from 20 × 5 µm kidney cryosections using the 
RNeasy Mini Plus Kit (Qiagen, Leusden, The Netherlands) according 
to the manufacturer's instructions. RNA integrity was analyzed, com-
plementary DNA synthesized, and quantitative reverse transcription 
polymerase chain reaction performed as described (Supplemental 
Digital Content 1, http://links.lww.com/CCX/A103).
Immunohistochemistry and Morphometric Analysis
Immunohistochemical staining of NGAL, KIM-1, and Neutrophil 
Elastase on formalin-fixed paraffin-embedded human kidney tis-
sue was performed as described (Supplemental Digital Content 1, 
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http://links.lww.com/CCX/A103). To quantify NGAL and 
KIM-1 immunostaining, the sections were first scanned using a 
Nanozoomer HT (Hamamatsu Photonics, Hamamatsu,  Japan). 
Morphometric analysis was performed using the Aperio Imagescope 
positive pixel analysis v9.1 algorithm (Aperio Technologies, Vista, 
CA) as described previously (23). Neutrophil infiltration was quan-
tified by counting the number of neutrophils (neutrophil Elastase 
positive) present in all glomeruli of the kidney sections.
Laser Microdissection
Cryosections (9 µm) were mounted on PolyEthylene Naphthalate–
membrane slides (Carl Zeiss B.V., Breda, The Netherlands), fixed, 
stained with Mayer hematoxylin, washed with diethylpyrocarbon-
ate-treated water, and air-dried. Glomeruli were laser microdis-
sected using the LMD6500 system (Leica Microsystems, Wetzlar, 
Germany) using LMD6500 software v7.0 (Leica Microsystems). 
Glomeruli (80–100) with a total area of 2 × 106 µm2 were dissected 
and collected in a 0.5-mL adhesive cap (Carl Zeiss B.V.) and stored 
at –80°C until gene expression analysis by reverse transcription 
quantitative polymerase chain reaction (RT-qPCR).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism Software 
v8 (San Diego, CA). Data are presented as mean ± sd. Statistical analy-
sis was performed using a two-tailed unpaired Student t test, assum-
ing unequal variances to compare two replicate means. Correlations 
between selected groups were assessed by Pearson tests. Differences 
were considered significant when p values were less than 0.05.
RESULTS
Renal NGAL and KIM-1 Levels Are Increased in Critically 
Ill Patients With Sepsis-AKI
Early detection of AKI and subtyping of AKI patients based on 
early pathophysiological parameters is critical to enable fast 
individualized therapeutic options for patients. We found sig-
nificantly higher renal NGAL and KIM-1 messenger RNA levels 
in sepsis-AKI biopsies when compared with control subjects 
(Fig. 1A). However, NGAL and KIM-1 messenger RNA levels 
did not correlate with each other (Fig. 1B).
We proceeded by investigating the localization of NGAL and 
KIM-1 staining in sepsis-AKI and control biopsies. NGAL staining 
was present in the distal tubules, collecting ducts, adventitia of the 
renal arterioles, and, surprisingly, in the glomerular tuft of renal 
biopsies from Sepsis-AKI patients. In control biopsies, NGAL was 
absent in the glomeruli and present in the distal tubules and col-
lecting ducts, but to a lesser extent than in Sepsis-AKI biopsies 
(Fig. 1C; and Supplemental Fig. 1, Supplemental Digital Content 
1, http://links.lww.com/CCX/A103). NGAL was virtually absent in 
proximal tubules in Sepsis-AKI and control biopsies (Fig. 1C; and 
Supplemental Fig. 1, Supplemental Digital Content 1, http://links.
lww.com/CCX/A103). KIM-1 staining was primarily localized 
at the brush border of the proximal tubular epithelium (Fig. 1C; 
and Supplemental Fig, 1, Supplemental Digital Content 1, http://
links.lww.com/CCX/A103). Morphometric analysis of the kidney 
biopsy sections found a clear increase in renal NGAL and KIM-1 
protein levels in sepsis-AKI biopsies when compared with con-
trol (Fig. 1D). Thus, both increased NGAL and KIM-1 messenger 
RNA and protein levels were found in sepsis-AKI compared with 
control biopsies, yet both injury markers were distributed differ-
ently within the kidney. No correlation was found between NGAL 
and KIM-1 messenger RNA or protein levels (Fig. 1, B and E) sug-
gesting a heterogeneous and independent up-regulation of both 
markers in patients with sepsis.
Renal NGAL and KIM-1 Protein Levels Do Not Correlate 
With the Severity of Critical Illness or the Extent of 
Renal Injury
Using the APACHE IV or the SAPS II scoring system, we found that 
NGAL and KIM-1 levels did not correlate with the severity of critical 
TABLE 1. Control Patients: Clinical, Laboratory, and Renal Function Details
Patient ID No. Age Sex Reason for Nephrectomy
Creatinine (d) Before  
Nephrectomy (µmol/L)
Creatinine (d) After  
Nephrectomy (µmol/L)
1 75 Female Renal cancer 82 (39) 108 (1)
2 61 Male Renal cancer 66 (41) 98 (1)
3 75 Female Renal cancer 65 (1) 93 (1)
4 49 Male Renal cancer 59 (1) 91 (1)
5 73 Male Renal cancer 72 (2) 89 (1)
6 62 Female Renal cancer 87 (on OR day, pre-OR) 94 (1)
7 79 Male Renal cancer 74 (1) 239 (1)
8 20 Female Renal cancer 80 (23) 424 (1)
9 44 Male Renal cancer 92 (20) 197 (1)
10 56 Female Renal cancer 63 (on OR day, pre-OR) 91 (1)
11 73 Female Renal cancer 58 (1) 54 (1)
12 47 Female Renal cancer 114 (15) 99 (8)
OR = operating room.
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TABLE 2. Sepsis-Associated Acute Kidney Injury Patients: Clinical, Laboratory, and Renal 
Function Details
Patient 
ID No. Age Sex
Days in 
ICU

























1 85 Male 3 Abdomen (gut ischemia)
Escherichia coli and Bacteroides 
fragilis (ascites)
74 I No 90 106
2 62 Male 1 Lungs Streptococcus pneumonia 
(sputum)
100 I No 166 166
3 62 Male 5 Abdomen (perforation cecum)
Klebsiella pneumoniae, 
Enterobacter cloacae, 
Enterococcus faecium, Candida 
Krusei
170 F Yes 199 98
4 62 Female 2 Hip (Fasciitis necroticans)
Negative blood culture
96 F No 355 344
5 57 Female 2 Abdomen (perforation colon 
ascendens)
Negative blood culture
129 F Yes 193 147
6 68 Female 4 Abdomen (bowel ischemia) negative 
sputum, urine, and rectal cultures
142 F Yes 89 87
7 55 Male 2 Pneumosepsis
Sputum pseudomonas, Aspergillus
ND I No 82 123
8 83 Female 1 Abdomen (bowel ischemia)
Negative blood cultures, feces- 
Clostridium toxin
98 I No 90 90
9 78 Male 2 Pneumonosepsis, later also 
abdomen (Leriche) Unknown, 
referral from other hospital
109 F Yes 419 475
10 79 Male 6 Left leg, Fasciitis necroticans
Streptococcus pyogenes (group A) 
(blood and tissue cultures)
89 F No 197 216
11 77 Male 3 Pneumonia E. coli, S. pneumonia 
(sputum)
153 F No 106 190
12 68 Female 7 Pneumonia (aspiration)
E. coli, yeast (sputum)
50 I No 81 73
13 53 Male 2 Pneumonosepsis Castellaniella 
defragrans
135 F Yes 306 233
14 83 Male 2 Meningitis, probably pneumonia S. 
pneumonia (blood)
175 F Yes 93 126
15 79 Male 4 Necrotizing pancreatitis and 
bowel ischemia (pus/ascites) 
Bacteroides thetaiotaomicron 
and Bacteroides caccae, E. coli, 
Citrobacter braakii, Clostridium 
clostridioforme
115 F Yes 161 104
16 75 Male 3 Suspected endocarditis (pacemaker 
pocket infection) Staphylococcus 
aureus (blood)
86 I No 135 401
(Continued)
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illness (Fig. 2A and data not shown). Additionally, the NGAL and 
KIM-1 protein levels were not dependent on the degree of renal injury, 
as characterized in the sepsis-AKI patients using the RIFLE criteria 
(Fig. 2B). They were also not related to serum creatinine levels at ICU 
admission (Fig. 2C) or on the day of expiration (Fig. 2D). The ori-
gin and type of infection also had no influence on the extent of renal 
NGAL or KIM-1 protein levels (Supplemental Fig. 2, Supplemental 
Digital Content 1, http://links.lww.com/CCX/A103). Taken together, 
these findings indicate that renal NGAL and KIM-1 expression levels 
are increased in sepsis-AKI patients but are not associated with the 
severity of critical illness, AKI severity, or the type of infection.
Glomerular NGAL Protein Levels Identify Glomerular 
Heterogeneity in Sepsis-AKI Patients
We found NGAL staining in the glomeruli of sepsis-AKI patients 
(Fig. 3A). This was an unexpected finding, which, to our knowledge, 
has not been described before. We morphometrically determined 
the amount of NGAL staining in the glomerular tuft for all glom-
eruli in all biopsies. The size of the glomerular tufts in the con-
trol and sepsis-AKI biopsies did not significantly differ (Fig. 3B). 
Glomerular NGAL staining intensity was significantly higher in 
sepsis-AKI patients than in control subjects (Fig. 3C). Minimal 
glomerular NGAL staining intensity was found in control subjects 
(Fig. 3D). In contrast, glomerular NGAL staining intensity in kid-
neys of sepsis-AKI patients was highly variable (Fig. 3D). Some 
sepsis-AKI biopsies presented similar glomerular NGAL levels 
as control subjects (n = 9), whereas very high glomerular NGAL 
levels were found in 11 sepsis-AKI patients. Intermediate levels of 
glomerular NGAL were found in seven sepsis-AKI patients (Fig. 
3D). Glomerular NGAL appeared to be associated with sepsis in 
particular because staining of renal biopsies from patients with 
acute and chronic organ rejection, in which inflammation plays an 
TABLE 2. (Continued). Sepsis-Associated Acute Kidney Injury Patients: Clinical, Laboratory, and 
Renal Function Details
Patient 
ID No. Age Sex
Days in 
ICU
























17 61 Male 2 Not known, likely abdomen E. coli 
(blood)
123 I No 190 269
18 76 Male 3 Abdomen (bowel ischemia) E. 
faecium (ascites)
89 F Yes 134 185
19 66 Male 12 Abdomen (bowel ischemia)
Candida krusei (blood), 
Enterococcus species (ascites)
ND F Yes 158 87
20 63 Male 3 Abdomen (neutropenic enterocolitis) 
Norovirus (feces)
146 I No 96 161
21 81 Male 2 Pneumonia Aspergillus 
fumigatus, Bordetella (sputum), 
Haemophilus (blood)
164 I No 350 370
22 63 Female 5 Aspiration pneumonitis. 
gastrointestinal bleeding Negative 
cultures
ND I No 184 360
23 40 Female 4 Urinary tract infection E. coli, 
Enterococcus faecalis (blood)
104 F Yes 108 160
24 81 Male 6 Pneumonia, abdomen (peritonitis)
Multibacterial (including anaerobic), 
Haemophilus influenzae (sputum)
ND I No 128 131
25 66 Female 2 Abdomen (Sigmoid perforation)
Multibacterial (including anaerobic)
191 F Yes 143 144
26 51 Female 2 Abdomen (spontaneous bacterial 
peritonitis)
Gram-negative bacilli, (ascites and 
blood)
205 F Yes 164 139
27 59 Female 4 Abdomen (perforation jejunum, 
duodenum)
E. coli (ascites)
103 I No 119 241
F = failure, I = injury, ND = not determined.
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Figure 1. Renal neutrophil gelatinase–associated lipocalin (NGAL) and[citation f1] kidney injury molecule (KIM)-1 levels are increased in critically ill patients 
with sepsis-associated acute kidney injury (Sepsis-AKI). A, Postmortem kidney biopsies were collected from patients with sepsis-AKI (n = 27). Kidney tissue 
was also obtained from control subjects (n = 12). NGAL and KIM-1 messenger RNA (mRNA) expression was determined by reverse transcription quantitative 
polymerase chain reaction using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. Each dot represents an individual subject, *p < 
0.05, **p < 0.005. B, NGAL mRNA levels do not correlate with KIM-1 mRNA levels as determined by Spearman correlation testing, r = –0.0184, p = 0.357. 
C, Representative immunohistochemical staining of NGAL (red) and KIM-1 (red) in a postmortem kidney biopsy from a sepsis-AKI patient compared with control 
renal tissue, original magnification ×400. D, Morphometric quantification of NGAL and KIM-1 staining in kidney biopsies from control (n = 12) and sepsis-AKI 
(n = 27) subjects. Graphs represent the total number of positive pixels per μm2. Each dot represents an individual subject, *p < 0.05, **p < 0.005. E, Renal NGAL 
protein levels do not correlate with KIM-1 protein levels as determined by Spearman correlation testing, r = –0.098, p = 0.631.
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important role, was devoid of NGAL positive glomeruli 
(data not shown).
To elucidate whether NGAL is trapped in glomeruli, 
for example, due to impaired filtration, or, alternatively, 
is produced by endogenous cells, we laser microdissected 
glomeruli and subjected them to RT-qPCR. NGAL mes-
senger RNA levels were not detectable in glomeruli of 
control subjects but could be detected in four of the five 
sepsis-AKI patients (Fig. 3E). Furthermore, high NGAL 
messenger RNA levels paralleled high glomerular NGAL 
protein staining (Fig. 3E). Intriguingly, NGAL protein 
levels did not correlate with the number of neutrophils 
present in the glomeruli of sepsis-AKI patients (Fig. 
3F), which suggests that glomerular NGAL expression 
is not derived from neutrophils present in the glomeruli. 
Taken together, our data indicate that NGAL protein 
is produced in the glomeruli of sepsis-AKI patients to 
varying degrees within one kidney and is not associated 
with the number of infiltrating neutrophils.
DISCUSSION
In critically ill patients, sepsis-AKI is associated with 
high morbidity and mortality (1). Many patients leaving 
the ICU are dialysis dependent or at risk of developing 
or accelerating progression of chronic kidney disease 
(24). In sepsis, many processes in multiple cell types act 
in unison to cause kidney injury. Among these processes 
are acute inflammation resulting from bacteria or cel-
lular products due to end-organ damage, microvascular 
dysfunction, and ischemic injury due to low blood pres-
sure, blood shunting, and intravascular coagulation (25). 
Paradoxically, therapies such as antibiotics and high 
chloride resuscitation fluid might also be nephrotoxic 
(26). However, not all of these detrimental processes 
will occur in all sepsis patients and to the same extent. 
Furthermore, not all of these injurious cellular processes 
will induce the same renal response because damage 
can be inflicted at the glomerular, microvascular, and/or 
tubular level (25). For example, renal tubules are known 
to respond differently to ischemia than to toxin or LPS 
exposure, all of which are prevalent in sepsis (15).
We investigated whether NGAL and KIM-1 could 
differentiate AKI patient phenotypes. NGAL is a 
N-glycosylated protein with partly elucidated functions 
(27). It has iron-chelating capacity and might play a role 
in iron-mediated bacteriostasis (28), and in endogenous 
metabolic processes mediating cell growth (29), apop-
tosis (30), metabolism, and rescue from ischemia (31). 
There is a low-grade continuous NGAL production in 
the liver (32), yet most organs can produce NGAL in 
response to toxic, inflammatory, or infectious cellular 
injury. Serum NGAL is significantly increased in patients 
with sepsis-AKI when compared with patients with non-
septic AKI (33). We found increased NGAL expression 
in the kidney from sepsis-AKI patients compared with 
control subjects. This expression was localized in the 
Figure 2. Renal neutrophil gelatinase–associated lipocalin (NGAL) and kidney injury 
molecule (KIM)-1 protein levels do not correlate with the severity of critical illness or the 
extent of renal injury. A, Renal NGAL and KIM-1 protein levels do not correlate with the 
severity of critical illness (Acute Physiology and Chronic Health Evaluation [APACHE IV] 
score) as determined by Spearman correlation analysis, r = 0.091, p = 0.678 (NGAL), 
r = –0.245, p = 0.259 (KIM-1). B, Renal NGAL and KIM-1 protein levels, represented by 
the total number of positive pixels per μm2 from sepsis-AKI patients (n = 27), were also 
categorized by the extent of renal injury, Risk, Injury, Failure, Loss of kidney function, and 
End-stage kidney disease (RIFLE) criteria. C, Serum creatinine levels from sepsis-AKI 
patients at ICU admission do not correlate with the amount of renal NGAL and KIM-1 
protein levels in biopsies from the same patients as determined by Spearman correlation 
analysis, r = 0.146, p = 0.467 (NGAL), r = –0.075, p = 0.715 (KIM-1). D, Serum creatinine 
levels from sepsis-AKI patients that did not receive renal replacement therapy, determined 
on the day of expiration, did not correlate with renal NGAL and KIM-1 protein levels as 
determined by Spearman correlation testing, r = 0.292, p = 0.288 (NGAL), r = –0.117,  
p = 0.975 (KIM-1).
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Figure 3. Glomerular neutrophil gelatinase–associated lipocalin (NGAL) protein levels identifies glomerular heterogeneity in sepsis-acute kidney injury (AKI) 
patients. A, Representative immunohistochemical staining of NGAL (red) in a postmortem kidney biopsy from a sepsis-AKI patient compared with control renal 
tissue, original magnification ×400. B, Violin plot of glomerulus size of all individual glomeruli per biopsy in control (n = 469 from 12 control biopsies) and sepsis-AKI 
patients (n = 406 from 27 sepsis-AKI biopsies). The solid lines indicate the median size of all glomeruli in control and sepsis-AKI subjects, respectively. C, Violin plot 
of glomerular NGAL positivity in all glomeruli tufts from all control (n = 12) and sepsis-AKI patients (n = 27). The solid lines indicate the median glomerular positivity 
in control and sepsis-AKI subjects, respectively. D, Glomerular NGAL positivity was determined in all glomeruli tufts within a renal biopsy from control subjects (n 
= 12) and sepsis-AKI (n = 27). Each dot represents the NGAL positivity within a single glomerulus within a single renal biopsy. Solid lines indicate the median 
glomerular positivity in that particular biopsy. The dashed lines indicate the mean size of all glomeruli in control and sepsis-AKI subjects, respectively. E, Glomerular 
NGAL messenger RNA levels were determined within the whole biopsy by reverse transcription quantitative polymerase chain reaction in control (n = 3) and 
sepsis-AKI patients (n = 5) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeping gene (gray bars, left axis). Dots indicate the individual 
glomerular NGAL positivity from the same control and sepsis-AKI patient (right axis). F, Glomerular NGAL protein levels determined in biopsies from sepsis-AKI 
patients do not correlate with the average number of neutrophils infiltrating glomeruli in the same sepsis-AKI patients. r = 0.109, p = 0.619.
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distal tubules and collecting ducts, corroborating previous findings 
(34). Surprisingly, we also found that glomeruli in kidneys from 
sepsis-AKI patients produced NGAL. However, not all glomeruli 
expressed NGAL to the same extent, even when they were adja-
cent. This observation implies that even within a short distance 
range, glomerular heterogeneity in human kidneys exists. It is 
well known that adjacent glomeruli vary in structure and possibly 
also in function. Previous studies have shown that some glomeruli 
appear normal, whereas others are sclerotic, despite a clinical pic-
ture of increased proteinuria and diminished glomerular filtration 
rate (35). Our data indicate that NGAL staining in the glomeru-
lus was not a result of impaired glomerular filtration but a conse-
quence of cells localized within the glomerulus producing NGAL. 
Neutrophils are known to produce and secrete NGAL; however, 
our previous study found only a few neutrophils in the glomerulus 
(18). Furthermore, we found no correlation between the amount 
of glomerular NGAL and the number of neutrophils localized in 
the glomerulus. Hence, glomerulus-specific cells, endothelial cells, 
podocytes, or mesangial cells may produce NGAL under sepsis 
conditions. LPS was previously found to induce NGAL expression 
in podocytes in culture and in glomeruli in vivo (36). Likewise, 
NGAL expression was previously found in macrophages, smooth 
muscle cells, and endothelial cells in human carotid atherosclerotic 
arteries (37). Hence, glomerular endothelial cells and podocytes 
may be able to produce NGAL under sepsis conditions.
KIM-1 is a transmembrane glycoprotein that is undetectable in 
normal healthy kidneys. However, the expression of KIM-1 is spe-
cifically induced in the kidney after ischemic or toxic injury and 
can be detected in the plasma and urine, highlighting the specific-
ity of KIM-1 for kidney injury (38, 39). KIM-1 is thought to be 
important for the removal of dead cells and the regeneration of 
tubular epithelial cells after injury (13). We found increased and 
considerable diverse expression of both KIM-1 messenger RNA 
and protein in sepsis-AKI patients. KIM-1 was found primar-
ily localized on the apical surface of a limited number of proxi-
mal tubular epithelial cells as well as in the cytoplasm in flat and 
stretched tubular epithelial cells within dilated tubules, corrobo-
rating previous findings (40).
Both renal injury markers were increased in the kidney of 
patients with sepsis, but a correlation between NGAL and KIM-1 
messenger RNA or protein expression was absent. The trigger 
inducing up-regulation of these biomarkers is known to be dif-
ferent (15), and the lack of correlation suggests that in different 
patients with the same consensus diagnosis, the balance between 
both response mechanisms is different which may be related to the 
kinetics of biomarker production. Hence, the pathophysiological 
mechanisms of kidney injury likely differ between sepsis-AKI 
patients.
A strength of our study is the use of kidney biopsies from sepsis-
AKI patients, which has allowed us to make associations among 
clinical data, pathology, and molecular changes albeit in a small 
cohort of patients. However, several limitations need to be consid-
ered. We analyzed a subpopulation of sepsis-AKI patients, namely 
nonsurvivors, which probably represent the most severe critically 
ill patients. Furthermore, the onset and duration of sepsis varied 
per patient, as did the length of ICU stay. Hence, the kinetics of 
renal biomarker production in the kidney is unknown. Ideally, we 
would have correlated plasma and urine levels of NGAL and KIM-1 
with the data presented here because this would have provided an 
insight into the relationship between the amounts of NGAL and 
KIM-1 found in the serum and/or urine and kidney pathophysi-
ology. Unfortunately, we currently do not have plasma or urine 
samples from this sepsis cohort, yet we plan to expand this cohort 
and will include blood and urine samples from the same patients.
CONCLUSIONS
We have shown that there is a difference in the expression of renal 
NGAL and KIM in patients with the same syndrome “sepsis-AKI.” 
The fact that the expression differs means that there is no single 
pathway leading to sepsis-AKI. This underscores the beliefs that 
there are many/different pathophysiological pathways that can 
cause sepsis-AKI. Hence, patients with criteria that meet the defi-
nitions of both AKI and sepsis can be divided into subtypes based 
on pathophysiological features.
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